Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis - European Radiology
Source : https://link.springer.com/article/10.1007/s00330-021-08233-w
Objectives In multiple sclerosis (MS), iron rim lesions (IRLs) are indicators of chronic low-grade inflammation and ongoing tissue destruction. The aim of this study was to assess the relationship of...
Conclusions
Relapsing MS patients with IRLs showed more aggressive MRI disease characteristics in both the cross-sectional and longitudinal analyses.
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis - Neurotherapeutics
Source : https://link.springer.com/article/10.1007/s13311-021-01104-8
Data regarding effectiveness and safety of ocrelizumab in the post-marking setting are lacking. The aim of our study was to provide effectiveness and safety data of ocrelizumab treatment in patients...
Conclusions
Our data point at ocrelizumab as an effective treatment option in patients with RRMS and PMS, especially for those patients who initiate ocrelizumab treatment in the early phase of the disease and for treatment-naïve patients. Depletion of CD8 cells could account for early therapeutic effects of ocrelizumab.
Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study - Neurological Sciences
Source : https://link.springer.com/article/10.1007/s10072-021-05612-5
Background Depression and anxiety are the two important factors determining quality of life of patients with multiple sclerosis (PWMS). In COVID-19 pandemic era, several factors can provoke mental issues of...
Conclusion
The overall prevalence of depressive symptoms in PWMS in our MS clinic is 51.4% which is obviously higher than other world’s centers which could be due to fear of COVID-19. In addition to fear of COVID-19, presence of depressive symptoms in PWMS is related significantly with level of education, number of hospital admissions due to MS...
Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report - Hubert Mado, Katarzyna Kubicka-Bączyk, Monika Adamczyk-Sowa, 2021
Source : https://doi.org/10.1177/03000605211044378
Abstract Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested...